[Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma].
Evidence based drug therapy is currently available for the treatment of prolactinomas and growth hormone secreting adenomas (acromegaly). Dopamine agonists such as bromocriptine, quinagolide or cabergoline represent the standard therapy for the treatment of micro- and macro-prolaktinomas. In pregnancy, more differentiated, individual and patient-adapted therapeutic procedures have to be considered. Transsphenoidal adenomectomy is the treatment of choice for patients suffering from acromegaly. If biochemical cure (defined by normalized IGF-1 serum levels or by a GH nadir <1 microg/l during a 3-h oral glucose tolerance test) cannot be achieved, somatostatin analogues such as octreotide and lanreotide are effective. In some cases, dopamine agonists can be added. In therapy-resistant cases, growth hormone receptor antagonists can be used.
Schäffler
A
A
Klinik und Poliklinik für Innere Medizin I, Universität Regensburg, Regensburg. andreas.schaeffler@klinik.uni-regensburg.de
D000172:Acromegaly / Q000209:etiology / Q000628:therapy*; D000236:Adenoma / Q000175:diagnosis / Q000628:therapy*; D003131:Combined Modality Therapy; D018492:Dopamine Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006964:Hyperpituitarism / Q000175:diagnosis / Q000628:therapy*; D007016:Hypophysectomy; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000628:therapy*; D011247:Pregnancy; D015175:Prolactinoma / Q000175:diagnosis / Q000628:therapy*; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
D018492:Dopamine Antagonists; D011986:Receptors, Somatotropin; D013004:Somatostatin